EPS for Theravance Biopharma, Inc. (TBPH) Expected At $-1.04

Theravance Biopharma, Inc. (NASDAQ:TBPH) Logo
Investors sentiment decreased to 1.19 in 2019 Q2. Its down 0.73, from 1.92 in 2019Q1. It dived, as 12 investors sold Theravance Biopharma, Inc. shares while 20 reduced holdings. 10 funds opened positions while 28 raised stakes. 34.36 million shares or 3.09% more from 33.32 million shares in 2019Q1 were reported.
Baupost Group Ltd Co Ma reported 9.31M shares. 21,877 were reported by Credit Suisse Ag. State Of New Jersey Common Pension Fund D owns 265,459 shares or 0.02% of their US portfolio. State Of Wisconsin Invest Board holds 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 62,600 shares. Charles Schwab Invest Mgmt holds 0% or 251,994 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 2,679 shares. Moreover, Morgan Stanley has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH). Public Employees Retirement Association Of Colorado invested in 10,856 shares or 0% of the stock. Parametric Port Limited Liability Corporation reported 18,551 shares. New York-based State Common Retirement Fund has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Engineers Gate Manager Lp reported 42,471 shares. Voya Invest Mgmt Lc invested in 18,830 shares. Daiwa Securities Group, Japan-based fund reported 353 shares. Grp Inc One Trading Lp accumulated 0.01% or 59,568 shares. Fosun invested 0.2% in Theravance Biopharma, Inc. (NASDAQ:TBPH).

Analysts expect Theravance Biopharma, Inc. (NASDAQ:TBPH) to report $-1.04 EPS on November, 5.They anticipate $0.06 EPS change or 5.45 % from last quarter’s $-1.1 EPS. After having $-0.72 EPS previously, Theravance Biopharma, Inc.’s analysts see 44.44 % EPS growth. The stock decreased 1.74% or $0.34 during the last trading session, reaching $19.15. About 111,400 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 10.59% since October 7, 2018 and is downtrending. It has underperformed by 10.59% the S&P500.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.05 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

More notable recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were published by: Seekingalpha.com which released: “An Updated Investment View On Theravance Biopharma – Seeking Alpha” on October 04, 2018, also Seekingalpha.com with their article: “An Updated View On Theravance Biopharma – Seeking Alpha” published on August 02, 2018, Prnewswire.com published: “Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension – PRNewswire” on January 28, 2019. More interesting news about Theravance Biopharma, Inc. (NASDAQ:TBPH) were released by: Seekingalpha.com and their article: “Theravance Biopharma: Prognosis Oversold – Seeking Alpha” published on December 03, 2018 as well as Fool.com‘s news article titled: “Theravance Biopharma Inc. (TBPH) Q1 2019 Earnings Call Transcript – The Motley Fool” with publication date: May 14, 2019.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.